New biologic drug shows promise for eczema in early trial
NCT ID NCT05277571
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new biologic drug called UCB1381 in 109 people, first in healthy volunteers and then in those with moderate to severe atopic dermatitis (eczema). The goal was to check safety and see if it improves eczema symptoms. Participants received either the drug or a placebo, and researchers tracked side effects and skin improvement over 12 to 22 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UCB1381 (a biologic drug given by injection or IV)
What this could lead to
If successful, this could point toward a new treatment option for people with moderate to severe eczema.
What could go wrong
This is an early phase 1/2A trial with only 109 participants, so results may not confirm effectiveness or safety for wider use. Side effects are possible, and the drug may not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Up0110 101
Glendale, California, 91206, United States
-
Up0110 102
St. Petersburg, Florida, 33705, United States
-
Up0110 104
Oklahoma City, Oklahoma, 73170, United States
-
Up0110 106
Ocala, Florida, 34471, United States
-
Up0110 107
New York, New York, 10029, United States
-
Up0110 108
Clearwater, Florida, 33765, United States
-
Up0110 109
Miami Lakes, Florida, 33014, United States
-
Up0110 111
College Park, Georgia, 30349, United States
-
Up0110 114
Minneapolis, Minnesota, 55455, United States
-
Up0110 116
Los Angeles, California, 90045, United States
-
Up0110 119
Philadelphia, Pennsylvania, 19103, United States
-
Up0110 121
Northridge, California, 91324, United States
-
Up0110 124
Winston-Salem, North Carolina, 27103, United States
-
Up0110 125
Beverly Hills, California, 90212, United States
-
Up0110 126
Tustin, California, 92780, United States
-
Up0110 127
Valencia, California, 91355, United States